Total neoadjuvant multidrug chemotherapy in the management of gastric cancer

Phase 2

Recruiting

• Conditions: Gastric cancer.; Malignant neoplasm of stomach, unspecified; C16.9

• Registration Number: IRCT20211211053356N1
• Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 63

Inclusion Criteria

Pathologically confirmed gastric adenocarcinoma in biopsy
Perigastric lymph node metastasis in CT scan
Resectable primary gastric tumor based on CT scan

Exclusion Criteria

Presence of distant metastasis at the presentation
Previous history of chemotherapy
Previous history of radiotherapy
Previous history of malignancy
Suffering from uncontrolled diabetes mellitus
Suffering from uncontrolled hypertension
No consent to enroll

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pathologic response. Timepoint: After the intervention and providing the pathologic report of gastrectomy. Method of measurement: Based on report of pathologist.

Secondary Outcome Measures

Name	Time	Method
Surgical margin status. Timepoint: After the intervention and providing the pathologic report of gastrectomy. Method of measurement: Based on pathologist report.;Treatment completion rate. Timepoint: During the intervention, every three week. Method of measurement: History taking.;Treatment toxicity. Timepoint: During the intervention, every three week. Method of measurement: history taking.